ZURICH, June 9, 2021 /PRNewswire/ — CDR-Life Inc., a biotherapeutics firm growing tumor-specific immunotherapies primarily based on a proprietary antibody platform, right this moment introduced the growth of its management crew with the appointment of Björn Peters as chief enterprise officer. On this newly created position, Mr. Peters, a extremely seasoned biotechnology and pharmaceutical govt, might be primarily chargeable for enterprise growth and can report on to Chief Government Officer, Christian Leisner, Ph.D.
“Björn’s addition to our administration crew marks an vital milestone for CDR-Life as we proceed to pursue strategic partnerships for our extremely revolutionary antibody therapies,” acknowledged Dr. Leisner. “Having spent greater than twenty years centered on enterprise growth, technique and administration inside the biotechnology and pharmaceutical arenas, Björn’s confirmed expertise and established relationships might be invaluable as we improve our visibility and look to develop alternatives for our tumor-specific T cell engagers.”
Mr. Peters added, “The concentrating on of intracellular antigens in tumor cells is a really promising strategy to realize higher efficacy and security outcomes and I’m honored to hitch such a crew of extremely skilled and achieved antibody specialists. I look ahead to collaborating with my colleagues to additional develop CDR-Life’s enterprise technique and to forge important new partnerships which can assist to progress the corporate’s rising portfolio of novel and promising immunotherapies throughout a spread of indications.”
Previous to becoming a member of CDR-Life, Mr. Peters served as head of enterprise growth at each Allecra Therapeutics and Zealand Pharma. Earlier in his profession, he held positions of accelerating accountability inside enterprise growth at Shire Prescribed drugs, Movetis (a spin-off from Johnson & Johnson, subsequently acquired by Shire Prescribed drugs) and Johnson & Johnson subsidiary, Janssen-Cilag. Throughout his tenure in enterprise growth, Mr. Peters has contributed to a profitable collection of each buy- and sell-side transactions with a complete worth exceeding $7 billon, together with the sale of Movetis to Shire after the corporate went public on Euronext.
About CDR-Life Inc.
CDR-Life, a biotherapeutics firm, develops novel immunotherapies that concentrate on the facility of the immune system particularly to tumor cells. Primarily based on a proprietary antibody platform that targets intracellular tumor antigens introduced on the key histocompatibility advanced (MHC) with excessive affinity and specificity, the corporate is advancing a portfolio of tumor-specific T cell engagers for the therapy of excessive want strong tumor malignancies. CDR-Life is led by former biologics inventors, pharmaceutical drug builders and firm builders, and has an present collaboration and licensing settlement with Boehringer Ingelheim for a novel antibody fragment remedy to deal with macular degeneration. For extra data, please go to www.cdr-life.com.
SOURCE CDR-Life Inc.